PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) platform for solid tumors offering personalized, ultra-sensitive detection of residual cancer. Built on Guardant’s Smart Platform, Reveal Ultra incorporates tumor-informed, patient-specific genomic alterations to provide one of the most advanced and actionable views of MRD. Validat

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.